Advanced Bioaerosols Technology Core

项目概要/摘要-先进生物气溶胶技术核心 先进生物气溶胶技术核心（ABTC）将开发一套全面的创新技术， 改进流感病毒气溶胶的取样、分离、培养和表征技术， 实现新的分析能力，以支持U19研究项目的目标。的先进技术 通过ABTC开发的技术将在每个单独的研究项目中使用， 空气传播和传染性研究，通过有效的环境采样相结合，以评估 感染性病毒在临床环境中的大小依赖性分布，以及高分辨率个体 呼出气采样，以阐明精确传输建模所需的基本源项。 ABTC团队将利用生物工程、生物气溶胶系统工程和生物技术领域的专业知识， 呼吸道病毒学将开发5种先进的生物气溶胶分析技术。在目标1中， 将开发一系列紧凑型仪器，用于收集和并行基于尺寸的环境分馏。 环境气溶胶，以便在拟议的临床研究期间对空气传播的病毒进行分布式监测。在 目标2，将推出第二款采用独特呼出气采样技术的气溶胶采样仪器 开发提供高分辨率的气溶胶分离和收集，使我们能够评估可行的， 来自个体供体的非感染性病毒排放跨越窄的颗粒尺寸范围。以增强传染性 为了表征采样的病毒颗粒，合成粘液水凝胶将在目标3中作为一种新的 环境采样器的采样目标，提供改进的病毒捕获和细胞培养，大大提高 用于下游感染性测定的病毒捕获和活力。数字化细胞培养阵列技术将 在目标4中开发的，能够直接分离由呼出气体捕获的单个气溶胶颗粒 采样器，并使我们能够评估存活和非感染性病毒单位的分布和聚集 单粒子分辨率ABTC团队还将开发一种优化的细胞系，用于 分析所收集的病毒，以加强评估病毒的传染性。芯会 通过一套系统验证气溶胶采样、捕获、分离、培养和分析的开发技术， 在与拟议的U19研究项目整合之前，将对雪貂进行研究，并将执行所需的检测 使用临床样本来支持RP 1和RP 2的目标。ABTC研究工作的结果将产生 加强我们对流感空气生物学的理解所需的仪器和技术， 确定评价环境中传染性颗粒分布的关键源项， 支持流感传播建模、风险分析和缓解的重大改进，同时 为我们进一步了解其他呼吸道病毒大流行的威胁做出了重要贡献。

Project Summary/Abstract – Advanced Bioaerosol Technology Core The Advanced Bioaerosol Technology Core (ABTC) will develop a comprehensive suite of innovative technologies for improved sampling, fractionation, culture, and characterization of influenza virus aerosols to enable new analytical capabilities in support of the U19 research project goals. The advanced technologies developed through the ABTC will be employed within each individual research project to yield more effective studies of airborne transmission and infectivity through a combination of efficient ambient sampling to evaluate size-dependent distributions of infective virus within the clinical environment, and high-resolution individual exhaled breath sampling to elucidate the fundamental source terms needed for accurate transmission modeling. The ABTC team will leverage expertise across the fields of bioengineering, bioaerosol system engineering, and respiratory virology to develop 5 interconnected technologies for advanced bioaerosol analysis. In Aim 1, a set of compact instruments will be developed for the collection and parallel size-based fractionation of ambient environmental aerosols to enable distributed monitoring of airborne virus during the proposed clinical studies. In Aim 2, a second aerosol sampling instrument employing a unique exhaled breath sampling technology will be developed to provide high resolution aerosol fractionation and collection, allowing us to evaluate both viable and non-infective virus emission from individual donors across narrow particle size ranges. To enhance infectivity characterization for sampled virus particles, a synthetic mucus hydrogel will be advanced in Aim 3 as a novel sample target for the environmental sampler, providing improved virus capture and cell culture, greatly improving virus capture and viability for downstream infectivity assays. A digital cell culture array technology will be developed in Aim 4, enabling the direct isolation of individual aerosol particles captured by the exhaled breath sampler, and allowing us to evaluate distribution and clustering of both viable and non-infective virus units at single particle resolution. The ABTC team will also develop an optimized cell line that will be employed for the analysis of virus collected with the developed instruments to enhance evaluation of infectivity. The core will validate the developed technologies for aerosol sampling, capture, isolation, culture, and analysis through a set of ferret studies before integration with the proposed U19 research projects, and will execute the required assays using clinical samples to support the goals of RP1 and RP2. The results of the ABTC research efforts will yield the instruments and technologies needed to enhance our understanding of influenza aerobiology, from the determination of critical source terms to the evaluation of infective particle distributions within the environment, supporting significant improvements to influenza transmission modeling, risk analysis, and mitigation, while making important contributions toward advancing our understanding of other respiratory viral pandemic threats.